Zevra Therapeutics, Inc. announced the transition of its Chief Financial Officer and Treasurer, R. LaDuane Clifton.
Mr. Clifton will step down from his position on December 31, 2025, to pursue other professional opportunities.
The company expresses gratitude for Mr. Clifton's contributions to its financial stability and growth.
Chief Financial Officer Transition
R. LaDuane Clifton to step down on December 31, 2025.
Search for Successor
Company initiating search for the next CFO.
Company Mission
Focused on providing therapies for rare diseases.
- Mr. Clifton's departure marks an important change in company leadership.
- The search for a new CFO signals a strategic move towards ensuring financial stability.
- Zevra's commitment to rare disease treatments remains strong despite the transition in leadership.
Zevra Therapeutics, Inc. is poised to navigate this transition smoothly and continue its mission of providing life-changing therapies for rare diseases with a solid financial foundation.